Connor, Clark & Lunn Investment Management (CC&L)’s Keros Therapeutics KROS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.55M | Buy |
265,707
+137,604
| +107% | +$1.84M | 0.01% | 678 |
|
|
2025
Q1 | $1.31M | Buy |
128,103
+98,957
| +340% | +$1.01M | 0.01% | 865 |
|
|
2024
Q4 | $461K | Buy |
+29,146
| New | +$461K | ﹤0.01% | 1162 |
|
|
2022
Q4 | – | Sell |
-9,620
| Closed | -$362K | – | 1329 |
|
|
2022
Q3 | $362K | Buy |
+9,620
| New | +$362K | ﹤0.01% | 880 |
|